At present, conventional clinical management of breast cancer mainly depends on the traditional prognostic factors, including patient’s age, molecular subtype, tumor size, lymph node metastasis, clinical stage, and histological grade, in addition to estrogen receptor (ER), progesterone receptor (PR), and HER2 [36, 37]. This evidence concerns the gene ERBB2 and breast carcinoma.